CM
JANX icon

Crestline Management’s Janux Therapeutics JANX Stock Holding History

Crestline Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,414
Closed -$1.25M – 331
2024
Q4 		$1.25M Buy
+23,414
New +$1.24M 0.04% 371

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Crestline Management's JANX Position: Q1 2025 in Review

Crestline Management sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 23,414 shares — an estimated $1.25M sold.

Crestline Management first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $1.25M in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Crestline Management reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 23,414 Janux Therapeutics shares in Q1 2025, an estimated $1.25M.
  • Crestline Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
  • Crestline Management's Janux Therapeutics position peaked at $1.25M in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.